# Presage Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/presage-biosciences

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.presagebio.com
- Total disclosed funding: $6M
- Latest round: Series D (Jul 17, 2018)
- Investors on record: 2

## About

Based in Seattle, US and founded in 2008, Presage Biosciences, Inc operates as a biotechnology company providing a new approach for evaluating drug responses in clinical trials. As of March 2021, Rich Klinghoffer is the CEO of the company. In March 2021, the company raised USD 13 million in funding from two financings, which are venture debt financing and venture funding. Through venture debt financing, the company raised USD 6 million funding led by Takeda Ventures while the company raised USD 7 million funding through venture funding led by LabCorp Venture Fund, Bristol Myers Squibb and InHarv Partners. As of result of funding from March 2021, the company has raised a total of USD 32.39 million. 

The company offers CIVO® (Comparative In Vivo Oncology) multiplexed intratumoral microdosing technology that allows clinical investigators to evaluate the localized tumor response to drug candidates in the tumor microenvironment along with capturing tumor heterogeneity and patient diversity.

Presage plans to use its proceeds from March 2021 financing to support the expansion of its existing clinical sites network in Australia and the US. Also, the company plans to develop next-generation CIVO microdose injection devices designed to access a wider spectrum of cancers.

## Funding rounds

- Series D, Jul 17, 2018, $6M — Takeda Ventures, Bristol-Myers Squibb Company

## Investors

- Takeda Ventures (https://capitalatlas.ai/funds/takeda-ventures) — Series D
- Bristol-Myers Squibb Company — Series D